Atrasentan hydrochloride (BioDeep_00000781236)
代谢物信息卡片
Atrasentan hydrochloride
化学式: C29H39ClN2O6 (546.2496504000001)
中文名称: 盐酸阿特拉森坦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4.Cl
InChI: /m1./s1
描述信息
C28313 - Endothelin Receptor Antagonist > C28334 - Endothelin Receptor Type A Antagonist
D065128 - Endothelin Receptor Antagonists > D065130 - Endothelin A Receptor Antagonists
D000970 - Antineoplastic Agents
Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective endothelin A receptor antagonist with an IC50 of 0.0551 nM for ETA[1].
同义名列表
数据库引用编号
7 个数据库交叉引用编号
- KEGGdrug: D03009
- KEGGdrug: D82853
- PubChem: 159595
- ChEMBL: CHEMBL2106068
- MeSH: Atrasentan
- CAS: 195733-43-8
- medchemexpress: HY-15403A
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- J David Smeijer, Jeroen Koomen, Donald E Kohan, John J V McMurray, George L Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, James L Januzzi, Dalane W Kitzman, Daniel M Kolansky, Hirofumi Makino, Vlado Perkovic, Sheldon Tobe, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J L Heerspink. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
JACC. Heart failure.
2022 Jul; 10(7):498-507. doi:
10.1016/j.jchf.2022.03.004. [PMID: 35772861] - Bożena Bądzyńska, Ivana Vaneckova, Janusz Sadowski, Silvie Hojná, Elżbieta Kompanowska-Jezierska. Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats.
European journal of pharmacology.
2021 Nov; 910(?):174445. doi:
10.1016/j.ejphar.2021.174445. [PMID: 34492284] - Yasser H Habib, Mennatallah A Gowayed, Sherien A Abdelhady, Nevine M El-Deeb, Inas E Darwish, Mahmoud M El-Mas. Modulation by antenatal therapies of cardiovascular and renal programming in male and female offspring of preeclamptic rats.
Naunyn-Schmiedeberg's archives of pharmacology.
2021 11; 394(11):2273-2287. doi:
10.1007/s00210-021-02146-7. [PMID: 34468816] - Hiddo J L Heerspink, Di Xie, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray, Vlado Perkovic, Peter Rossing, Hans-Henrik Parving, Dick de Zeeuw. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
Journal of the American Society of Nephrology : JASN.
2021 11; 32(11):2900-2911. doi:
10.1681/asn.2021030391. [PMID: 34551995] - Simke W Waijer, Sieta T de Vries, Robert Busch, Di Xie, Ron T Gansevoort, Fan Fan Hou, Jose L Górriz, Gozewijn D Laverman, Luca De Nicola, Julio Pascual, Michele Provenzano, Pablo E Pergola, Sydney C W Tang, Christoph Wanner, Philippe Zaoui, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J L Heerspink. Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy: A Post Hoc Analysis from the SONAR Trial.
Journal of the American Society of Nephrology : JASN.
2021 11; 32(11):2731-2734. doi:
10.1681/asn.2021040498. [PMID: 34417318] - Yasser H Habib, Sherien A Abdelhady, Mennatallah A Gowayed, Nevine M El-Deeb, Inas E Darwish, Mahmoud M El-Mas. Prenatal endothelin or thromboxane receptor antagonism surpasses sympathoinhibition in improving cardiorenal malfunctions in preeclamptic rats.
Toxicology and applied pharmacology.
2021 09; 426(?):115615. doi:
10.1016/j.taap.2021.115615. [PMID: 34102242] - J David Smeijer, Donald E Kohan, David J Webb, Neeraj Dhaun, Hiddo J L Heerspink. Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
Current opinion in nephrology and hypertension.
2021 07; 30(4):456-465. doi:
10.1097/mnh.0000000000000716. [PMID: 33990507] - Jeroen V Koomen, Jasper Stevens, George Bakris, Ricardo Correa-Rotter, Fan Fan Hou, Dalane W Kitzman, Donald E Kohan, Hirofumi Makino, John J V McMurray, Hans-Henrik Parving, Vlado Perkovic, Sheldon W Tobe, Dick de Zeeuw, Hiddo J L Heerspink. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Clinical pharmacology and therapeutics.
2021 06; 109(6):1631-1638. doi:
10.1002/cpt.2143. [PMID: 33338269] - Cleo C L van Aanhold, Kyra L Dijkstra, Manon Bos, Ron Wolterbeek, Bernard M van den Berg, Jan A Bruijn, Ingeborg M Bajema, Hans J Baelde. Reduced Glomerular Endothelial Thrombomodulin Is Associated with Glomerular Macrophage Infiltration in Diabetic Nephropathy.
The American journal of pathology.
2021 05; 191(5):829-837. doi:
10.1016/j.ajpath.2021.02.002. [PMID: 33617784] - Michele Provenzano, Michele Andreucci, Carlo Garofalo, Roberto Minutolo, Raffaele Serra, Luca De Nicola. Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease.
Expert opinion on investigational drugs.
2021 Mar; 30(3):253-262. doi:
10.1080/13543784.2021.1869720. [PMID: 33356648] - Jeroen V Koomen, Jasper Stevens, George Bakris, Ricardo Correa-Rotter, Fan Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray, Hans-Henrik Parving, Vlado Perkovic, Sheldon W Tobe, Dick de Zeeuw, Hiddo J L Heerspink. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
Diabetes, obesity & metabolism.
2021 02; 23(2):561-568. doi:
10.1111/dom.14252. [PMID: 33184931] - Y Zhou, J Chi, Y Huang, B Dong, W Lv, Y G Wang. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Diabetic medicine : a journal of the British Diabetic Association.
2021 01; 38(1):e14411. doi:
10.1111/dme.14411. [PMID: 33000477] - Eman Y Gohar, David M Pollock. Functional Interaction of Endothelin Receptors in Mediating Natriuresis Evoked by G Protein-Coupled Estrogen Receptor 1.
The Journal of pharmacology and experimental therapeutics.
2021 01; 376(1):98-105. doi:
10.1124/jpet.120.000322. [PMID: 33127751] - Dongwei Liu, Zhangsuo Liu. Atrasentan in patients with diabetes and chronic kidney disease.
Lancet (London, England).
2020 01; 395(10220):269-270. doi:
10.1016/s0140-6736(19)33021-1. [PMID: 31982064] - Vincenzo Sepe, Carmelo Libetta. Atrasentan in patients with diabetes and chronic kidney disease.
Lancet (London, England).
2020 01; 395(10220):269. doi:
10.1016/s0140-6736(19)33020-x. [PMID: 31982065] - Hiddo J L Heerspink, Hans-Henrik Parving, Dick de Zeeuw. Atrasentan in patients with diabetes and chronic kidney disease - Authors' reply.
Lancet (London, England).
2020 01; 395(10220):270. doi:
10.1016/s0140-6736(19)32995-2. [PMID: 31982067] - Masaomi Nangaku. Light of dawn in Melbourne: SONAR and CREDENCE.
Kidney international.
2019 07; 96(1):2-4. doi:
10.1016/j.kint.2019.04.004. [PMID: 31229029] - Jie Wang, Lanyu Shen, Hong Hong, Jie Li, Hongtai Wang, Xiuzhen Li. Atrasentan alleviates high glucose-induced podocyte injury by the microRNA-21/forkhead box O1 axis.
European journal of pharmacology.
2019 Jun; 852(?):142-150. doi:
10.1016/j.ejphar.2019.03.013. [PMID: 30876973] - Susanne Brenner, Christoph Wanner. [Diabetic Kidney Disease - How to Protect the Kidney?].
Deutsche medizinische Wochenschrift (1946).
2019 06; 144(11):710-714. doi:
10.1055/a-0662-1919. [PMID: 31163466] - Hiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray, Joel Z Melnick, Michael G Miller, Pablo E Pergola, Vlado Perkovic, Sheldon Tobe, Tingting Yi, Melissa Wigderson, Dick de Zeeuw. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Lancet (London, England).
2019 05; 393(10184):1937-1947. doi:
10.1016/s0140-6736(19)30772-x. [PMID: 30995972] - Katherine R Tuttle. A turning point for chronic kidney disease in diabetes.
Lancet (London, England).
2019 05; 393(10184):1913-1914. doi:
10.1016/s0140-6736(19)30855-4. [PMID: 30995973] - Marcel H A Muskiet, David C Wheeler, Hiddo J L Heerspink. New pharmacological strategies for protecting kidney function in type 2 diabetes.
The lancet. Diabetes & endocrinology.
2019 05; 7(5):397-412. doi:
10.1016/s2213-8587(18)30263-8. [PMID: 30579729] - Hiddo J L Heerspink, Dennis L Andress, George Bakris, John J Brennan, Ricardo Correa-Rotter, Fan Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John McMurray, Vlado Perkovic, Sheldon Tobe, Melissa Wigderson, Tingting Yi, Hans-Henrik Parving, Dick de Zeeuw. Baseline characteristics and enrichment results from the SONAR trial.
Diabetes, obesity & metabolism.
2018 08; 20(8):1829-1835. doi:
10.1111/dom.13315. [PMID: 29604160] - Jeroen V Koomen, Jasper Stevens, Nael M Mostafa, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J L Heerspink. Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.
Diabetes, obesity & metabolism.
2018 08; 20(8):2019-2022. doi:
10.1111/dom.13312. [PMID: 29603851] - Hiddo J L Heerspink, Dennis L Andress, George Bakris, John J Brennan, Ricardo Correa-Rotter, Jyotirmoy Dey, Fan Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John McMurray, Vlado Perkovic, Sheldon Tobe, Melissa Wigderson, Hans-Henrik Parving, Dick de Zeeuw. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
Diabetes, obesity & metabolism.
2018 06; 20(6):1369-1376. doi:
10.1111/dom.13245. [PMID: 29405626] - Chih-Wei Lin, Nael M Mostafa, Dennis L Andress, John J Brennan, Cheri E Klein, Walid M Awni. Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy.
Clinical therapeutics.
2018 02; 40(2):242-251. doi:
10.1016/j.clinthera.2017.07.011. [PMID: 28756065] - Suellen C Coelho, Olga Berillo, Antoine Caillon, Sofiane Ouerd, Júlio C Fraulob-Aquino, Tlili Barhoumi, Stefan Offermanns, Pierre Paradis, Ernesto L Schiffrin. Three-Month Endothelial Human Endothelin-1 Overexpression Causes Blood Pressure Elevation and Vascular and Kidney Injury.
Hypertension (Dallas, Tex. : 1979).
2018 01; 71(1):208-216. doi:
10.1161/hypertensionaha.117.09925. [PMID: 29133362] - David J Webb, Blai Coll, Hiddo J L Heerspink, Dennis Andress, Yili Pritchett, John J Brennan, Mark Houser, Ricardo Correa-Rotter, Donald Kohan, Hirofumi Makino, Vlado Perkovic, Giuseppe Remuzzi, Sheldon W Tobe, Robert Toto, Robert Busch, Pablo Pergola, Hans-Henrik Parving, Dick de Zeeuw. Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
Drugs in R&D.
2017 Sep; 17(3):441-448. doi:
10.1007/s40268-017-0201-0. [PMID: 28831752] - Jesus Egido, Jorge Rojas-Rivera, Sebastian Mas, Marta Ruiz-Ortega, Ana Belen Sanz, Emilio Gonzalez Parra, Carmen Gomez-Guerrero. Atrasentan for the treatment of diabetic nephropathy.
Expert opinion on investigational drugs.
2017 Jun; 26(6):741-750. doi:
10.1080/13543784.2017.1325872. [PMID: 28468519] - Michelle J Pena, Dick de Zeeuw, Dennis Andress, John J Brennan, Ricardo Correa-Rotter, Blai Coll, Donald E Kohan, Hirofumi Makino, Vlado Perkovic, Giuseppe Remuzzi, Sheldon W Tobe, Robert Toto, Hans-Henrik Parving, Shoba Sharma, Tom Corringham, Kumar Sharma, Hiddo J L Heerspink. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
Diabetes, obesity & metabolism.
2017 05; 19(5):749-753. doi:
10.1111/dom.12864. [PMID: 28019071] - Jacob Gibbens, Rachael Morris, Teylor Bowles, Shauna-Kay Spencer, Kedra Wallace. Dysregulation of the Fas/FasL system in an experimental animal model of HELLP syndrome.
Pregnancy hypertension.
2017 Apr; 8(?):26-30. doi:
10.1016/j.preghy.2017.02.004. [PMID: 28501275] - Hiddo J L Heerspink, Hirofumi Makino, Dennis Andress, John J Brennan, Ricardo Correa-Rotter, Blai Coll, Justin W Davis, Ken Idler, Donald E Kohan, Mohan Liu, Vlado Perkovic, Giuseppe Remuzzi, Sheldon W Tobe, Robert Toto, Hans-Henrik Parving, Dick de Zeeuw. Comparison of exposure response relationship of atrasentan between North American and Asian populations.
Diabetes, obesity & metabolism.
2017 04; 19(4):545-552. doi:
10.1111/dom.12851. [PMID: 27981738] - Richard Larivière, Alexandra Gauthier-Bastien, Roth-Visal Ung, Julie St-Hilaire, Fabrice Mac-Way, Darren E Richard, Mohsen Agharazii. Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease.
Journal of hypertension.
2017 02; 35(2):376-384. doi:
10.1097/hjh.0000000000001161. [PMID: 28005706] - Lenka Sedláková, Věra Čertíková Chábová, Šárka Doleželová, Petra Škaroupková, Libor Kopkan, Zuzana Husková, Lenka Červenková, Soňa Kikerlová, Ivana Vaněčková, Janusz Sadowski, Elzbieta Kompanowska-Jezierska, Petr Kujal, Herbert J Kramer, Luděk Červenka. Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2017; 39(2):183-195. doi:
10.1080/10641963.2016.1235184. [PMID: 28287881] - Erika I Boesen. Lack of an apparent role for endothelin-1 in the prolonged reduction in renal perfusion following severe unilateral ischemia-reperfusion injury in the mouse.
Physiological reports.
2016 11; 4(21):. doi:
10.14814/phy2.13027. [PMID: 27905299] - Matthew D Breyer, Katalin Susztak. Developing Treatments for Chronic Kidney Disease in the 21st Century.
Seminars in nephrology.
2016 11; 36(6):436-447. doi:
10.1016/j.semnephrol.2016.08.001. [PMID: 27987541] - Jermaine G Johnston, Joshua S Speed, Chunhua Jin, David M Pollock. Loss of endothelin B receptor function impairs sodium excretion in a time- and sex-dependent manner.
American journal of physiology. Renal physiology.
2016 11; 311(5):F991-F998. doi:
10.1152/ajprenal.00103.2016. [PMID: 27582096] - Margien G S Boels, M Cristina Avramut, Angela Koudijs, Martijn J C Dane, Dae Hyun Lee, Johan van der Vlag, Abraham J Koster, Anton Jan van Zonneveld, Ernst van Faassen, Hermann-Josef Gröne, Bernard M van den Berg, Ton J Rabelink. Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy.
Diabetes.
2016 08; 65(8):2429-39. doi:
10.2337/db15-1413. [PMID: 27207530] - Duygu Batu Demir, Mark E Cooper. New strategies to tackle diabetic kidney disease.
Current opinion in nephrology and hypertension.
2016 07; 25(4):348-54. doi:
10.1097/mnh.0000000000000234. [PMID: 27138228] - Bauke Schievink, Dick de Zeeuw, Paul A Smink, Dennis Andress, John J Brennan, Blai Coll, Ricardo Correa-Rotter, Fan Fan Hou, Donald Kohan, Dalane W Kitzman, Hirofumi Makino, Hans-Henrik Parving, Vlado Perkovic, Giuseppe Remuzzi, Sheldon Tobe, Robert Toto, Jarno Hoekman, Hiddo J Lambers Heerspink. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
European journal of preventive cardiology.
2016 May; 23(7):758-68. doi:
10.1177/2047487315598709. [PMID: 26229089] - Wen-Ling Kang, Gao-Si Xu. Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy.
Scientific reports.
2016 Jan; 6(?):19979. doi:
10.1038/srep19979. [PMID: 26813039] - Michael A Carducci, Judith Manola, Suresh G Nair, Glenn Liu, Steven Rousey, Janice P Dutcher, George Wilding. Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).
Clinical genitourinary cancer.
2015 Dec; 13(6):531-539.e1. doi:
10.1016/j.clgc.2015.07.002. [PMID: 26272427] - Suttira Intapad, Norma B Ojeda, Elliott Varney, Thomas P Royals, Barbara T Alexander. Sex-Specific Effect of Endothelin in the Blood Pressure Response to Acute Angiotensin II in Growth-Restricted Rats.
Hypertension (Dallas, Tex. : 1979).
2015 Dec; 66(6):1260-6. doi:
10.1161/hypertensionaha.115.06257. [PMID: 26459423] - Donald E Kohan, Hiddo J Lambers Heerspink, Blai Coll, Dennis Andress, John J Brennan, Dalane W Kitzman, Ricardo Correa-Rotter, Hirofumi Makino, Vlado Perkovic, Fan Fan Hou, Giuseppe Remuzzi, Sheldon W Tobe, Robert Toto, Hans-Henrik Parving, Dick de Zeeuw. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
Clinical journal of the American Society of Nephrology : CJASN.
2015 Sep; 10(9):1568-74. doi:
10.2215/cjn.00570115. [PMID: 26153128] - Yohann Rautureau, Suellen C Coelho, Julio C Fraulob-Aquino, Ku-Geng Huo, Asia Rehman, Stefan Offermanns, Pierre Paradis, Ernesto L Schiffrin. Inducible human endothelin-1 overexpression in endothelium raises blood pressure via endothelin type A receptors.
Hypertension (Dallas, Tex. : 1979).
2015 Aug; 66(2):347-55. doi:
10.1161/hypertensionaha.115.05168. [PMID: 26101346] - Tobias F Kröpelin, Dick de Zeeuw, Dennis L Andress, Maarten J Bijlsma, Frederik Persson, Hans-Henrik Parving, Hiddo J Lambers Heerspink. Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
Clinical journal of the American Society of Nephrology : CJASN.
2015 Mar; 10(3):410-6. doi:
10.2215/cjn.07780814. [PMID: 25568217] - Mohammed A Samad, Ui Kyoung Kim, Joshua J Kang, Qingen Ke, Peter M Kang. Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner.
PloS one.
2015; 10(3):e0121664. doi:
10.1371/journal.pone.0121664. [PMID: 25775254] - Ping Qi, Ming Chen, Li-xiu Zhang, Rui-xia Song, Zhen-hua He, Zhi-ping Wang. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
PloS one.
2015; 10(7):e0133803. doi:
10.1371/journal.pone.0133803. [PMID: 26192308] - Chunhua Jin, Yejoo Jeon, Daniel T Kleven, Jennifer S Pollock, John J White, David M Pollock. Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.
The Journal of pharmacology and experimental therapeutics.
2014 Nov; 351(2):467-73. doi:
10.1124/jpet.114.215566. [PMID: 25189702] - Sergio Stefoni, Giuseppe Cianciolo, Olga Baraldi, Mario Iorio, Maria Laura Angelini. Emerging drugs for chronic kidney disease.
Expert opinion on emerging drugs.
2014 Jun; 19(2):183-99. doi:
10.1517/14728214.2014.900044. [PMID: 24836744] - Islam R Younis, Daniel J George, Terence J McManus, Herbert Hurwitz, Patricia Creel, Andrew J Armstrong, Jing Jie Yu, Kristina Bacon, Gerald Hobbs, Cody J Peer, William P Petros. Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.
Cancer chemotherapy and pharmacology.
2014 May; 73(5):991-7. doi:
10.1007/s00280-014-2432-x. [PMID: 24619498] - Dick de Zeeuw, Blai Coll, Dennis Andress, John J Brennan, Hui Tang, Mark Houser, Ricardo Correa-Rotter, Donald Kohan, Hiddo J Lambers Heerspink, Hirofumi Makino, Vlado Perkovic, Yili Pritchett, Giuseppe Remuzzi, Sheldon W Tobe, Robert Toto, Giancarlo Viberti, Hans-Henrik Parving. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
Journal of the American Society of Nephrology : JASN.
2014 May; 25(5):1083-93. doi:
10.1681/asn.2013080830. [PMID: 24722445] - Tsung-Ming Lee, Tun-Hui Chung, Shinn-Zong Lin, Nen-Chung Chang. Endothelin receptor blockade ameliorates renal injury by inhibition of RhoA/Rho-kinase signalling in deoxycorticosterone acetate-salt hypertensive rats.
Journal of hypertension.
2014 Apr; 32(4):795-805. doi:
10.1097/hjh.0000000000000092. [PMID: 24463935] - Primo N Lara, Benjamin Ely, David I Quinn, Philip C Mack, Catherine Tangen, Erik Gertz, Przemyslaw W Twardowski, Amir Goldkorn, Maha Hussain, Nicholas J Vogelzang, Ian M Thompson, Marta D Van Loan. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
Journal of the National Cancer Institute.
2014 Apr; 106(4):dju013. doi:
10.1093/jnci/dju013. [PMID: 24565955] - Cynthia Ritter, Sarah Zhang, Jane L Finch, Helen Liapis, Edu Suarez, Leon Ferder, James Delmez, Eduardo Slatopolsky. Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats.
Kidney & blood pressure research.
2014; 39(4):340-52. doi:
10.1159/000355811. [PMID: 25300759] - Kathleen D Liu. Therapeutic strategies for clinical trials targeting renal recovery.
Nephron. Clinical practice.
2014; 127(1-4):113-6. doi:
10.1159/000363703. [PMID: 25343832] - Richard A Zager, Ali C M Johnson, Dennis Andress, Kirsten Becker. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.
Kidney international.
2013 Oct; 84(4):703-12. doi:
10.1038/ki.2013.157. [PMID: 23698233] - I Brochu, M Houde, L Desbiens, E Simard, F Gobeil, W Semaan, G Bkaily, P D'Orléans-Juste. High salt-induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722.
British journal of pharmacology.
2013 Sep; 170(2):266-77. doi:
10.1111/bph.12259. [PMID: 23713522] - Deborah Stuart, Mark Chapman, Sara Rees, Stephanie Woodward, Donald E Kohan. Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention.
The Journal of pharmacology and experimental therapeutics.
2013 Aug; 346(2):182-9. doi:
10.1124/jpet.113.205286. [PMID: 23709116] - Roderick J Tan, Lili Zhou, Dong Zhou, Lin Lin, Youhua Liu. Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy.
PloS one.
2013; 8(11):e79963. doi:
10.1371/journal.pone.0079963. [PMID: 24265790] - Kimihiro Kimura, Mamoru Ohkita, Maki Koyama, Yasuo Matsumura. Reduced NO production rapidly aggravates renal function through the NF-κB/ET-1/ETA receptor pathway in DOCA-salt-induced hypertensive rats.
Life sciences.
2012 Oct; 91(13-14):644-50. doi:
10.1016/j.lfs.2012.04.022. [PMID: 22569294] - Dennis L Andress, Blai Coll, Yili Pritchett, John Brennan, Mark Molitch, Donald E Kohan. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
Life sciences.
2012 Oct; 91(13-14):739-42. doi:
10.1016/j.lfs.2012.01.011. [PMID: 22326504] - Kedra Wallace, Sarah Novotny, Judith Heath, Janae Moseley, James N Martin, Michelle Y Owens, Babbette LaMarca. Hypertension in response to CD4(+) T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system.
American journal of physiology. Regulatory, integrative and comparative physiology.
2012 Jul; 303(2):R144-9. doi:
10.1152/ajpregu.00049.2012. [PMID: 22647295] - Katty X Wan, Michael T Reimer, Maria P Metchkarova, Amy J Richter, Auratip Paramadilok, Olga Kavetskaia, Tawakol El-Shourbagy. Toxicokinetic evaluation of atrasentan in mice utilizing serial microsampling: validation and sample analysis in GLP study.
Bioanalysis.
2012 Jun; 4(11):1351-61. doi:
10.4155/bio.12.91. [PMID: 22720653] - G Groenewegen, M Walraven, J Vermaat, B de Gast, E Witteveen, R Giles, J Haanen, E Voest. Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma.
British journal of cancer.
2012 Jan; 106(2):284-9. doi:
10.1038/bjc.2011.515. [PMID: 22215065] - Ivana Vaněčková, Petr Kujal, Zuzana Husková, Zdeňka Vaňourková, Zdenka Vernerová, Věra Certíková Chábová, Petra Skaroupková, Herbert J Kramer, Vladimír Tesař, Luděk Červenka. Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
Kidney & blood pressure research.
2012; 35(5):382-92. doi:
10.1159/000336823. [PMID: 22487948] - Mohamed A Saleh, Jennifer S Pollock, David M Pollock. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease.
The Journal of pharmacology and experimental therapeutics.
2011 Jul; 338(1):263-70. doi:
10.1124/jpet.111.178988. [PMID: 21471190] - M A Saleh, E I Boesen, J S Pollock, V J Savin, D M Pollock. Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes.
Diabetologia.
2011 Apr; 54(4):979-88. doi:
10.1007/s00125-010-2021-4. [PMID: 21191784] - Ton J Rabelink, Donald E Kohan. Endothelin receptor blockade in patients with diabetic nephropathy.
Contributions to nephrology.
2011; 172(?):235-242. doi:
10.1159/000328703. [PMID: 21894003] - Erika I Boesen, David M Pollock. Cooperative role of ETA and ETB receptors in mediating the diuretic response to intramedullary hyperosmotic NaCl infusion.
American journal of physiology. Renal physiology.
2010 Dec; 299(6):F1424-32. doi:
10.1152/ajprenal.00015.2010. [PMID: 20844020] - Mohamed A Saleh, Erika I Boesen, Jennifer S Pollock, Virginia J Savin, David M Pollock. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat.
Hypertension (Dallas, Tex. : 1979).
2010 Nov; 56(5):942-9. doi:
10.1161/hypertensionaha.110.156570. [PMID: 20823379] - Martin Reriani, Eugenia Raichlin, Abhiram Prasad, Verghese Mathew, Geralyn M Pumper, Rebecca E Nelson, Ryan Lennon, Charanjit Rihal, Lilach O Lerman, Amir Lerman. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.
Circulation.
2010 Sep; 122(10):958-66. doi:
10.1161/circulationaha.110.967406. [PMID: 20733096] - Gerard D'Angelo, Analia S Loria, David M Pollock, Jennifer S Pollock. Endothelin activation of reactive oxygen species mediates stress-induced pressor response in Dahl salt-sensitive prehypertensive rats.
Hypertension (Dallas, Tex. : 1979).
2010 Aug; 56(2):282-9. doi:
10.1161/hypertensionaha.110.152629. [PMID: 20547970] - Erika I Boesen, Jennifer S Pollock, David M Pollock. Contrasting effects of intervention with ETA and ETB receptor antagonists in hypertension induced by angiotensin II and high-salt diet.
Canadian journal of physiology and pharmacology.
2010 Aug; 88(8):802-7. doi:
10.1139/y10-051. [PMID: 20725138] - Arnaud Mansart, Lewis J Ruff, Mark P Ariaans, Jonathan J Ross, Charles S Reilly, Nicola J Brown, Susan Kaufman, Zoë L S Brookes. Constriction of rat extra-splenic veins to lipopolysaccharide involves endothelin-1.
Naunyn-Schmiedeberg's archives of pharmacology.
2010 Jun; 381(6):555-62. doi:
10.1007/s00210-010-0514-9. [PMID: 20397012] - Roland C E Francis, Claudia Höhne, Adrian Klein, Udo X Kaisers, Philipp A Pickerodt, Willehad Boemke. Endothelin receptor subtype A blockade does not affect the haemodynamic recovery from haemorrhage during xenon/remifentanil or isoflurane/remifentanil anaesthesia in dogs.
Veterinary anaesthesia and analgesia.
2010 May; 37(3):258-68. doi:
10.1111/j.1467-2995.2010.00530.x. [PMID: 20230551] - Sydney R Murphy, B Babbette D LaMarca, Kathy Cockrell, Joey P Granger. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats.
Hypertension (Dallas, Tex. : 1979).
2010 Feb; 55(2):394-8. doi:
10.1161/hypertensionaha.109.141473. [PMID: 20026766] - Babbette LaMarca, Marc Parrish, Lillian Fournier Ray, Sydney R Murphy, Lyndsay Roberts, Porter Glover, Gerd Wallukat, Katrin Wenzel, Kathy Cockrell, James N Martin, Michael J Ryan, Ralf Dechend. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.
Hypertension (Dallas, Tex. : 1979).
2009 Oct; 54(4):905-9. doi:
10.1161/hypertensionaha.109.137935. [PMID: 19704104] - Zdenka Vanourková, Herbert J Kramer, Michaela Erbanová, Angela Bäcker, Ludek Cervenka, Zuzana Husková, Vera Certíková Chábová, Vladimír Tesar, Pavel Dvorák, Jan Malý, Ivana Vanecková. Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension.
Vascular pharmacology.
2009 May; 50(5-6):194-9. doi:
10.1016/j.vph.2009.01.002. [PMID: 19563737] - Daisuke Nakano, David M Pollock. Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats.
Hypertension (Dallas, Tex. : 1979).
2009 Feb; 53(2):324-30. doi:
10.1161/hypertensionaha.108.123687. [PMID: 19104001] - Andrew J Armstrong, Patricia Creel, James Turnbull, Cassandra Moore, Tracy A Jaffe, Sherri Haley, William Petros, Sarah Yenser, Jon P Gockerman, Darryl Sleep, Herbert Hurwitz, Daniel J George. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008 Oct; 14(19):6270-6. doi:
10.1158/1078-0432.ccr-08-1085. [PMID: 18829508] - Eugenia Raichlin, Abhiram Prasad, Verghese Mathew, Bailey Kent, David R Holmes, Geralyn M Pumper, Rebecca E Nelson, Lilach O Lerman, Amir Lerman. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis.
Hypertension (Dallas, Tex. : 1979).
2008 Sep; 52(3):522-8. doi:
10.1161/hypertensionaha.108.113068. [PMID: 18695150] - Jean-Claude Honoré, Emilie Carrier, Marie-Hélène Fecteau, Carlos R Tirapelli, Ghassan Bkaily, Pedro D'Orleans-Juste. Nonselective ETA/ETB-receptor blockade increases systemic blood pressure of Bio 14.6 cardiomyopathic hamsters.
Canadian journal of physiology and pharmacology.
2008 Jun; 86(6):394-401. doi:
10.1139/y08-041. [PMID: 18516103] - Claudia Höhne, Roland C E Francis, Philipp Pickerodt, Adrian Klein, Udo Kaisers, Willehad Boemke. ETA-receptor blockade impairs vasoconstriction after hemorrhage in xenon-anesthetized dogs treated with an AT1-receptor antagonist.
Canadian journal of physiology and pharmacology.
2008 Jun; 86(6):373-9. doi:
10.1139/y08-038. [PMID: 18516101] - Tsung-Ming Lee, Chien-Chang Chen, Mei-Shu Lin, Nen-Chung Chang. Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
American journal of physiology. Heart and circulatory physiology.
2008 Apr; 294(4):H1871-9. doi:
10.1152/ajpheart.01129.2007. [PMID: 18281380] - Zaid Abassi, Bishara Bishara, Tony Karram, Samer Khatib, Joseph Winaver, Aaron Hoffman. Adverse effects of pneumoperitoneum on renal function: involvement of the endothelin and nitric oxide systems.
American journal of physiology. Regulatory, integrative and comparative physiology.
2008 Mar; 294(3):R842-50. doi:
10.1152/ajpregu.00691.2007. [PMID: 18160528] - Gregory Fink, Melissa Li, Yanny Lau, John Osborn, Stephanie Watts. Chronic activation of endothelin B receptors: new model of experimental hypertension.
Hypertension (Dallas, Tex. : 1979).
2007 Sep; 50(3):512-8. doi:
10.1161/hypertensionaha.107.094821. [PMID: 17664390] - Mostafa M Elgebaly, Vera Portik-Dobos, Kamakshi Sachidanandam, David Rychly, Daniel Malcom, Maribeth H Johnson, Adviye Ergul. Differential effects of ET(A) and ET(B) receptor antagonism on oxidative stress in type 2 diabetes.
Vascular pharmacology.
2007 Aug; 47(2-3):125-30. doi:
10.1016/j.vph.2007.05.006. [PMID: 17597010] - Hao Xiong, Robert A Carr, Charles S Locke, David A Katz, Ramanuj Achari, Thao T Doan, Perry Wang, James R Jankowski, Darryl J Sleep. Dual effects of rifampin on the pharmacokinetics of atrasentan.
Journal of clinical pharmacology.
2007 Apr; 47(4):423-9. doi:
10.1177/0091270007299928. [PMID: 17389551] - Jennifer M Sasser, Jennifer C Sullivan, Janet L Hobbs, Tatsuo Yamamoto, David M Pollock, Pamela K Carmines, Jennifer S Pollock. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism.
Journal of the American Society of Nephrology : JASN.
2007 Jan; 18(1):143-54. doi:
10.1681/asn.2006030208. [PMID: 17167119] - Alejandro R Chade, James D Krier, Stephen C Textor, Amir Lerman, Lilach O Lerman. Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia.
Journal of the American Society of Nephrology : JASN.
2006 Dec; 17(12):3394-403. doi:
10.1681/asn.2006060635. [PMID: 17082239] - M Dror Michaelson, Donald S Kaufman, Philip Kantoff, William K Oh, Matthew R Smith. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Cancer.
2006 Aug; 107(3):530-5. doi:
10.1002/cncr.22043. [PMID: 16804927] - Gerald Wölkart, Heike Stessel, Zora Saad, Michael Kirchengast, Friedrich Brunner. Cardioprotective effects of atrasentan, an endothelin-A receptor antagonist, but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase.
British journal of pharmacology.
2006 Jul; 148(5):671-81. doi:
10.1038/sj.bjp.0706772. [PMID: 16702986] - David A Katz, Robert Carr, David R Grimm, Hao Xiong, Rhonda Holley-Shanks, Toby Mueller, Brenda Leake, Qiang Wang, Lixin Han, Perry G Wang, Timi Edeki, Leonardo Sahelijo, Thao Doan, Andrew Allen, Brian B Spear, Richard B Kim. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
Clinical pharmacology and therapeutics.
2006 Mar; 79(3):186-96. doi:
10.1016/j.clpt.2005.11.003. [PMID: 16513443] - Vera Portik-Dobos, Alex K Harris, Weiwei Song, Jimmie Hutchinson, Maribeth H Johnson, John D Imig, David M Pollock, Adviye Ergul. Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes.
American journal of physiology. Regulatory, integrative and comparative physiology.
2006 Feb; 290(2):R435-41. doi:
10.1152/ajpregu.00300.2005. [PMID: 16239374] - Perry G Wang, Jack Wei, Min Chang, Tawakol El-Shourbagy. High-throughput determination of atrasentan in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Biomedical chromatography : BMC.
2005 Nov; 19(9):663-70. doi:
10.1002/bmc.493. [PMID: 15803446] - Ivana Vanêcková, Herbert J Kramer, Angela Bäcker, Zdena Vernerová, Martin Opocensky, Ludêk Cervenka. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats.
Hypertension (Dallas, Tex. : 1979).
2005 Oct; 46(4):969-74. doi:
10.1161/01.hyp.0000173426.06832.b5. [PMID: 16157796] - Jean-Claude Honoré, Marie-Hélène Fecteau, Isabelle Brochu, Julie Labonté, Ghassan Bkaily, Pedro D'Orleans-Juste. Concomitant antagonism of endothelial and vascular smooth muscle cell ETB receptors for endothelin induces hypertension in the hamster.
American journal of physiology. Heart and circulatory physiology.
2005 Sep; 289(3):H1258-64. doi:
10.1152/ajpheart.00352.2005. [PMID: 15879484] - Alex K Harris, Jim R Hutchinson, Kamakshi Sachidanandam, Maribeth H Johnson, Anne M Dorrance, David W Stepp, Susan C Fagan, Adviye Ergul. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1.
Diabetes.
2005 Sep; 54(9):2638-44. doi:
10.2337/diabetes.54.9.2638. [PMID: 16123352]